MINNEAPOLIS, July 7, 2011 /PRNewswire/ -- ProUroCare Medical
Inc. (OTCQB: PUMD), a provider of proprietary medical imaging
products announced today the election of Larry W. Getlin to its Board of Directors.
During the past eight months, Getlin has served as a consultant
to the company assisting on its FDA "de novo" market
clearance application for its ProUroScan™ system and in developing
an effective communication channel with the agency. He has
also been instrumental in addressing strategic issues for the
company related to current and future regulatory actions.
According to Rick Carlson,
ProUroCare's CEO, "Larry is an outstanding addition to our Board
bringing 19 years of urology regulatory, clinical affairs, quality
and compliance experience. We believe this experience and the
relationships he has established within the medical device industry
and the global regulatory environment over his 35-year career will
be important to us as we pursue new FDA clearances and establish
the internal compliance programs required to enter the prostate
disease market. His background is representative of the
caliber of personnel we intend to add to our Board and management
teams moving forward."
Getlin served as Senior Vice President of Corporate Compliance,
Legal and Quality at American Medical Systems from June of 2006 to
April of 2010, and as Vice President of Regulatory, Clinical
Affairs and Quality Systems for 15 years before that time.
Prior to joining American Medical Systems he directed U.S. and
international regulatory approval programs and GMP compliance
initiatives at the Pharmaseal Division of Baxter Healthcare for
over 14 years. Getlin contributed to the revised and restated
AdvaMed Code of Ethics on Interactions with Health Care
Professionals. He is also a member of the California State
Bar Association, American Bar Association, Health Law Section and
the Regulatory Affairs Professional Society (RAPS).
About ProUroCare Medical Inc.
ProUroCare Medical Inc. is a publicly traded company engaged in
the business of developing innovative medical imaging products.
The company's ProUroScan system, an elasticity imaging
technology used to document abnormalities of the prostate
previously detected by a digital rectal examination, is currently
under review by the FDA for commercial clearance.
Safe Harbor Statement
This news release contains certain "forward-looking"
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as "believes," "expects," "anticipates," "intends,"
"will," "may," "should," or similar expressions. These
forward-looking statements are not guarantees of ProUroCare's
future performance and involve a number of risks and uncertainties
that may cause actual results to differ materially from the results
discussed in these statements. Factors that might
cause ProUroCare's results to differ materially from those
expressed or implied by such forward looking statements
include, but are not limited to, the ability of ProUroCare to find
adequate financing to complete the development of its products; the
high level of secured and unsecured debt incurred by
ProUroCare; the impact and timing of actions taken by the FDA and
other regulatory agencies with respect to ProUroCare's products and
business; the dependence by ProUroCare on third parties for
the development and manufacture of its products; and other risks
and uncertainties detailed from time to time in ProUroCare's
filings with the Securities and Exchange Commission including its
most recently filed Form 10-K and Form 10-Q.
ProUroCare undertakes no duty to update any of these
forward-looking statements.
SOURCE ProUroCare Medical Inc.